A CDMO that has made a habit of snapping up Big Pharma’s discarded manufacturing plants has put a former AstraZeneca plant into bankruptcy.
Avara Avlon Pharma Services, called in administrators after a major contract came to an end, BristolLive reports. The company is looking for a buyer for the site in Avonmouth, England, in an effort to save 270 jobs.
“Avlon has experienced financial difficulties in recent months as a result of a major contract with a customer coming to an end,” said accountant and insolvency specialist David Rubin, who with his partner Asher Miller has been named to oversee the administration, BristolLive reported. “The joint administrators are now managing the site, whilst they seek a buyer for the business and assets.”
When Avara acquired the API plant from AstraZeneca plant in 2016, terms were not disclosed but the drugmakers said Avara would manufacture products for AstraZeneca on a contract basis as part of the deal. The newspaper says AstraZeneca remains its sole customer.
Rubin said “the major customer” has agreed to provide short-term funding but if a buyer is not found by April the employees will be let go.
The plant has been on the brink of closure for years. AstraZeneca in 2014 said that it would close it by 2017 after generics undermined sales of high-cholesterol drug Crestor and bipolar treatment Seroquel whose APIs were manufactured there. AstraZeneca has closed or is closing other facilities as it remakes its manufacturing network as part of a $1.1 billion cost-cutting plan.
This was the second plant AstraZeneca sold to the Norwalk, Connecticut-based CDMO. In 2017, it sold Avara a solid dose facility in Reims, France, which also includes packaging and distribution operations.
In about three year’s time, Avara has bought nine sites from drugmakers like AstraZeneca, Pfizer and GlaxoSmithKline who were looking to unload unneeded facilities. It saved hundreds of jobs in the process. Avara agreed to keep on 500 workers at a sterile manufacturing facility and nearby development center in Boucherville, Quebec that it agreed to buy from Novartis last year. The site is the biggest injectables production facility in Canada and provides drugs to the Canadian healthcare system.
By Eric Palmer
Source: Fierce Pharma
As Novo Nordisk gears up to disrupt the obesity market with its newly approved weight-loss drug Wegovy, it is teaming with retail pharmacy giant CVS Health on a new education and nutrition coaching program for people taking anti-obesity meds.
The terms of the deal were undisclosed, but Atreca received $6 million from the Gates Foundation in 2012 to discover potential treatments for malaria, tuberculosis and HIV. The foundation has also given grant money to other biopharmas exploring malaria treatments, including Exscientia, which secured $4.2 million last year for such work.
At the start of the last decade, the IPO markets weren’t receptive to biotech companies. But by 2013, public investment was pouring into the industry, drawn by scientific advances and boosted by the newfound interest of a broader range of investors. Ever since, biotechs and their backers have ridden a multi-year boom. Keep track of them as they happen with this database.